DrugPatentWatch - Biopharmaceutical Business Intelligence
Profile for Alkermes plc (ALKS)
« Back to company indexALKS Chatter Timeline
Stock Ticker for ALKS
Most Active Tweeters for ALKS
| User | Tweets |
|---|---|
| @sleekoptions | 4 |
| @ConsumerFeed | 4 |
| @gcassidy718 | 3 |
| @AmericanBanking | 3 |
| @TickerReport | 2 |
Recent Tweets for ALKS
 |
@1stOncology #Alkermes Announces New Data From #ALKS4230 Clinical Development Program at #SITC19 $ALKS https://t.co/ghZEk8bLUK November 10th 2019, 10:11am |
 |
@TickerReport Michael J. Landine Sells 20,000 Shares of Alkermes Plc $ALKS Stock https://t.co/veSOwB8LMl November 10th 2019, 8:11am |
 |
@dailypoliticaln Alkermes Plc $ALKS SVP Sells $395,200.00 in Stock https://t.co/1IoAEUpCFp November 10th 2019, 8:11am |
 |
@TranscriptDaily Alkermes Plc $ALKS CEO Sells $1,382,638.95 in Stock https://t.co/eBieI4xtfK November 10th 2019, 6:11am |
 |
@stocknewstimes Richard F. Pops Sells 69,795 Shares of Alkermes Plc $ALKS Stock https://t.co/gd5QJFjY3t November 10th 2019, 6:11am |
 |
@Gambiste1 RT @gcassidy718: $ALKS I’ll probably buy on the dip. Still need to do more research. 2.08 % https://t.co/hUvnS3GBI1 November 10th 2019, 12:11am |
 |
@gcassidy718 $ALKS I’ll probably buy on the dip. Still need to do more research. 2.08 % https://t.co/hUvnS3GBI1 November 9th 2019, 10:11pm |
 |
@bbnsnews Richard F. Pops Sells 69,795 Shares of Alkermes Plc $ALKS Stock https://t.co/6ptQchNKZ0 November 9th 2019, 8:11am |
 |
@ConsumerFeed Alkermes SVP Michael Landine Sells $395,200.00 in $ALKS https://t.co/AXqeQXv2LP November 9th 2019, 3:11am |
|
@ConsumerFeed Alkermes CEO Richard Pops Sells $1,382,638.95 in $ALKS https://t.co/678IieyQeW November 9th 2019, 3:11am |
 |
@AmericanBanking Michael J. Landine Sells 20,000 Shares of Alkermes Plc $ALKS Stock https://t.co/8RoAdYkKXP #stocks November 8th 2019, 7:11pm |
 |
@bs2537 $ALKS at #SITC2019 https://t.co/syuKWC44Pi November 8th 2019, 7:11pm |
|
@AmericanBanking Richard F. Pops Sells 69,795 Shares of Alkermes Plc $ALKS Stock https://t.co/j3fVL4CPSC #stocks November 8th 2019, 7:11pm |
|
@TickerReport Alkermes Plc $ALKS CEO Richard F. Pops Sells 69,795 Shares https://t.co/RaGjfOLvi9 November 8th 2019, 7:11pm |
 |
@WatchlistN Richard F. Pops Sells 69,795 Shares of Alkermes Plc $ALKS Stock https://t.co/AsGMfgLu2b November 8th 2019, 6:11pm |
|
@gcassidy718 $ALKS Looking for any entry here......... ;) 2.06 % change recently https://t.co/hUvnS3GBI1 November 8th 2019, 5:11pm |
 |
@MonitorAction $ALKS Michael Landine Dumps 20K Shares of Alkermes plc. https://t.co/nADxRH1XfW November 8th 2019, 4:11pm |
 |
@InsiderAlertsIA $ALKS: New Insider Filing on Director and CEO, Alkermes plc RICHARD F POPS: https://t.co/Sbepyy4c7e November 8th 2019, 4:11pm |
 |
@sleekoptions Peak profit for the last 6 expired option alerts for $ALKS -14.29 % | -2.86 % | -1.60 % | 165.71 % | -10.26 % | -3.… https://t.co/GvEalPT2yP November 8th 2019, 2:11pm |
|
@sleekoptions $ALKS - View historical options performance for ALKS https://t.co/8OWl95LwVV https://t.co/KP8qCkOSuP November 8th 2019, 2:11pm |
|
@sleekoptions $ALKS - Last six months, 2 option alerts peaked above 100% after they were triggered by the algo… https://t.co/dxHARW6ZN1 November 8th 2019, 2:11pm |
 |
@Briefingcom $ALKS: Alkermes presents new data from ARTISTRY clinical development program related to ALKS 4230 at the Society fo… https://t.co/WdJNBWWyRv November 8th 2019, 9:11am |
 |
@IncredibleTrade Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunother... $ALKS… https://t.co/MSMEc1zTMg November 8th 2019, 8:11am |
 |
@EpiscopalianTra $ALKS Preliminary Safety and Efficacy Data From ARTISTRY-1 Show Signs of Clinical Benefit and Tolerability of ALKS… https://t.co/ICHNO0ZsXb November 8th 2019, 8:11am |
 |
@WallStCards $ALKS: Preliminary Safety and Efficacy Data From ARTISTRY-1 Show Signs of Clinical Benefit and Tolerability of ALKS… https://t.co/KnOjvVGelJ November 8th 2019, 7:11am |
 |
@newswelldone $ALKS: Alkermes Announces New Data From ALKS 4230 Clinical …: https://t.co/UlxXoFA7xr November 8th 2019, 7:11am |
|
@gcassidy718 $ALKS what a Company 2.64 % change recently https://t.co/hUvnS3GBI1 November 7th 2019, 5:11pm |
|
@EpiscopalianTra Does anybody know how much this will worth to $ALKS? They do have upcoming data release and I want to know about th… https://t.co/dT1nbQUhrK November 6th 2019, 2:11pm |
|
@1stOncology #Alkermes to Present Data From #ALKS4230 Clinical Development Program at #SITC19 $ALKS https://t.co/pnM3ykb6Xv November 5th 2019, 7:11am |
 |
@TheMarketsDaily Alkermes $ALKS Given New $26.00 Price Target at HC Wainwright https://t.co/qfwDGEHeHD November 5th 2019, 3:11am |
 |
@OlympiaReport Alkermes $ALKS PT Lowered to $26.00 at HC Wainwright https://t.co/C6Wl5v5DgO November 4th 2019, 5:11pm |
 |
@dispatchtribune Alkermes $ALKS PT Lowered to $26.00 at HC Wainwright https://t.co/jHVgpg2bTN November 4th 2019, 5:11pm |
 |
@WeekHerald Alkermes $ALKS Price Target Cut to $26.00 https://t.co/vBcKYoLBrY November 4th 2019, 5:11pm |
 |
@ThisLincolnian Alkermes $ALKS Price Target Cut to $26.00 https://t.co/Xlrj9tMkXn November 4th 2019, 5:11pm |
 |
@SwingTradeBot Recent $ALKS technical alerts: MACD Bullish Centerline Cross plus 5 more alerts... https://t.co/LZXCqc9JTR November 4th 2019, 1:11pm |
|
@biostockinfo RT @TomSilver39: Leerink:" #SitC2019 SITC Planner Highlights: data from $ALKS is likely to shape expectations for other “not alpha” interle… November 4th 2019, 10:11am |
 |
@TomSilver39 Leerink:" #SitC2019 SITC Planner Highlights: data from $ALKS is likely to shape expectations for other “not alpha”… https://t.co/1Mc9eZeXXS November 4th 2019, 10:11am |
 |
@adamfeuerstein $HALO is like a smaller $ALKS — good at helping other companies improve the delivery/administration of their drugs,… https://t.co/LzQLbSBPXD November 4th 2019, 7:11am |
|
@newswelldone $ALKS: Alkermes to Present Data From ALKS 4230 Clinical Development …: https://t.co/9xF1z3HyhF November 4th 2019, 7:11am |
 |
@ProVesting $ALKS $MRK: The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC …: https://t.co/Llsuds4UL8 November 3rd 2019, 11:11am |
 |
@DataTrials $ALKS Phase 3 Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals…NCT03711318.… https://t.co/uaYleMYu6u November 2nd 2019, 9:11am |
|
@AmericanBanking Alkermes $ALKS Receives Neutral Rating from HC Wainwright https://t.co/DHcNOofrtr #stocks November 1st 2019, 10:11pm |
 |
@marketexclusive $ALKS Alkermes Plc (NASDAQ:ALKS) had its Neutral rating reiterated by HC Wainwright with a $26.00 price target… https://t.co/6qEWdtao4v November 1st 2019, 10:11am |
 |
@BlueBioNow $ALKS Turn Green.. NOT Red... -3.01 % https://t.co/pOSy7CeMJf October 31st 2019, 9:10pm |
|
@SwingTradeBot 50 DMA Resistance today: $NBY $ALKS ... https://t.co/mnYaiRq1wk October 31st 2019, 12:10pm |
 |
@bs2537 Alkermes (NASDAQ: ALKS), Revisting Before Upcoming ALKS-4230 Immuno-Oncology Data $ALKS: https://t.co/IG8TBQz5Wu October 31st 2019, 10:10am |
 |
@ChartMill $ALKS: The EPS has grown by an impressive 81.08% over the past year. https://t.co/gWBFt1TJWR https://t.co/ErJFKGfPsM October 30th 2019, 4:10pm |
 |
@BankTheTrade $ALKS(20.02) up 2.20 (ALKS) said Wednesday that U.S. Food and Drug Administration approved Vumerity for the treat… https://t.co/RYy8nNYScp October 30th 2019, 8:10am |
 |
@Hall8Jack RT @BioStocks: $BIIB and $ALKS Announce FDA Approval Of VUMERITY For Multiple Sclerosis October 30th 2019, 8:10am |
 |
@1MinuteStock Not sure what to do with $ALKS? Explore our #fundamental pros and cons. https://t.co/T7pUyDYuUE October 30th 2019, 8:10am |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2019. All rights reserved.